cis-Methyl isoeugenol is a low-level phenylpropanoid ether that appears in some spice-like and calamus-related volatile profiles, but its public literature is much thinner than that of isoeugenol, methyl eugenol, or beta-asarone. In this research pass, the clearest evidence supports identity, analytical occurrence, and cautionary safety context rather than strong constituent-specific benefit claims. AromaForge should therefore present cis-methyl isoeugenol as a trace aromatic marker with limited direct bioactivity evidence and a prudent, metabolism-aware safety framing.
Chemical identity and composition
PubChem maps cis-methyl isoeugenol to the Z-configured isoeugenyl methyl ether record with formula C11H14O2 and InChIKey NNWHUJCUHAELCL-PLNGDYQASA-N. NIST and PubChem both support the cis or Z naming, while the archive currently captures this constituent in Calamus Root at 1.27%, where it sits alongside far more dominant asarones.
Aroma and practical use
- Use the recorded spicy, clove-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
acori region variation marker
A full-text Acori tatarinowii essential-oil study identified cis-methyl isoeugenol among eight volatile constituents that changed significantly across regional samples, but the strongest bioactivity correlations were assigned to beta- and gamma-asarone rather than cis-methyl isoeugenol.
Measured: constituent variation by region
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
prohapten screening signal
A toxicology abstract reported that methyl isoeugenol showed little or weak reporter induction without S9 but significantly enhanced induction with metabolic activation, supporting a prohapten interpretation in that assay system.
Measured: luciferase induction after metabolic activation
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe Good Scents page reviewed in this pass lists (Z)-methyl isoeugenol as a natural substances and extractives material and shows the recommendation 'not for fragrance use.'
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The most directly accessible mechanistic safety signal located here concerns methyl isoeugenol as a potential prohapten after metabolic activation rather than strong direct reactivity in the unactivated assay.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No constituent-specific human exposure standard, dermal clinical study, or robust therapeutic evidence for the cis isomer was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
metabolic activation as prohapten concern
A modified KeratinoSens assay paper reported that methyl isoeugenol behaved as a prohapten candidate, showing weak induction without metabolic activation and stronger luciferase induction in the presence of rat liver S9 fractions.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No strong constituent-specific human clinical or pharmacology literature for the cis isomer was verified in this pass.
- Most accessible biological literature discusses methyl isoeugenol more generally or focuses on other co-occurring calamus phenylpropanoids.
- Public safety context is clearer than public efficacy context for cis-methyl isoeugenol.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.